Six Things You Need to Know about Life Sciences M&A During and After COVID-19

Event Details

Please join AGG attorneys Brian A. Teras and Joel N. Gossner for a complimentary webinar on April 23, 2020: “Six Thing You Need to Know about Life Sciences M&A During and After COVID-19.”

While life sciences M&A activity soared to a new high in 2019, the uncertainty surrounding the pandemic has led to a slow down in deal making activity. However, as the crisis in the U.S. subsides and the U.S. economy stabilizes, we expect life sciences deals to resume in the near term. Further, valuations for small to mid-size life sciences companies are likely to decrease, creating buying opportunities for strategic and financial buyers with access to capital. We also expect to see an increase in the use of alternative deal structures to accommodate sellers in need of capital. On the positive side, historically, the life sciences industry has weathered the storm of prior economic slowdowns better than many other industries.

In this webinar, we’ll dive into six things you need to know about life sciences transactions during and after the COVID-19 pandemic. Join AGG partner Brian A. Teras and senior associate Joel N. Gossner as they review and discuss:

• Deal structures in a distressed deal-making environment
• Due diligence considerations
• Reps and warranties
• Representation and warranty insurance for life sciences transactions (including COVID-19 considerations)
• Impact of the pandemic and economic crisis on interim operating covenants and conditions to closing
• Practical and logistical implications for closing deals

Who’ll benefit from listening in? Senior executives, corporate business development personnel, and in-house legal counsel.

CLE credits: This webinar has been approved for 1 hour of Continuing Legal Education (CLE) credit by the State Bar of Georgia.

For more information, please click here to register or contact Mr. Teras or Mr. Gossner.